Cargando…
Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk
Pioglitazone and other thiazolidinediones (TZDs) initially showed great promise as unique receptor-mediated oral therapy for type 2 diabetes, but a host of serious side effects, primarily cardiovascular, have limited their utility. It is crucial at this point to perform a risk– benefit analysis to d...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3764952/ https://www.ncbi.nlm.nih.gov/pubmed/24023518 http://dx.doi.org/10.2147/VHRM.S34421 |